Intravitreal injections today: the challenges

An IVEG course at EURETINA 2025
Highlights and take-home messages

Jay Chablani, MD
Intravitreal injection sin vitrectomized eyes
- After PPV, the vitreous gel is replaced by aqueous humor, and this increases diffusion and shortens the pharmacokinetic half-life of anti-VEGF drugs. More frequent injections might be needed.
- These patients may benefit from longer-acting drugs with larger molecular weights
- Steroids may be considered, as they have slower clearance than anti-VEGF, but monitoring IOP is mandatory
- When injecting:
- avoid prior scleral wounds, and use a tunneled 30-32G needle;
- expect more reflux, apply prolonged compression
- In silicon oil-filled eyes, inject slowly, consider the inferior quadrant
Patricia Udaondo, MD, PhD
Intravitreal injections in patients with glaucoma
- Intravitreal injections are generally safe in patients with glaucoma, but the risk of causing RNFL changes and disease progression appears to be higher with frequent (>7) injections.
- Longer intervals between injections may help minimize IOP elevation. Nowadays, we have new treatments that allow us to maintain the efficacy with extended intervals.
- Prophylactic IOP-lowering medications are effective in reducing the risk.
- Closer monitoring is mandatory.


Gemmy Cheung, MD
Intravitreal injection in pregnant and breastfeeding women
- VEGF is important during the first trimester of pregnancy, as it is involved in the embryonic vascular development, as well as in maintaining the placenta throughout the pregnancy.
- There are anecdotal reports of miscarriage following anti-VEGF intravitreal injections in women with diabetes, but it is unsure whether these might be due to the anti-VEGF injection or to poor diabetes control
- Data are limited, and interpretation is challenging due to potential reporting bias, unbalanced risk factor profile and difficulty in ascertaining cause and effect relationship
- Steroids might be a safer option
- The use of these drugs during pregnancy and breast-feeding should be discussed case by case, involving a multidisciplinary team
Francesco Boscia, MD
Intravitreal injections: logistics, patient flow and adherence
- 96,624 injections analyzed showed no significant differences between office, ambulatory surgery and OR in terms of safety, with an identical 0.02% endophthalmitis rate
- Office-based injections lead to a reduction of 26% of cost and 14% productivity increase, and office is preferred by patients due to comfort and quick service
- Same day assessment and injection leads to cost savings, reduced travel burden, quality of life improvement
- A T&E injection regimen is non inferior to monthly and reduces the burden, with most patients achieving a Q12 or more interval
- Reasons for non-adherence are patient dissatisfaction, financial burden, age and comorbidities, travel distances and time, appointment booking difficulties.
- Same day assessment and injection, individualized T&E regimens and optimized care pathways correlate with better adherence.


Daniele Veritti, MD
Intravitreal injections, bilateral and symultaneous
- Same-day, bilateral anti-VEGF injections are increasingly used worldwide in real-would retina practice
- Large studies and meta-analyses show no increased risk of endophthalmitis
- Logistic and clinical benefits include fewer visits, better adherence, reduced burden for the patient and the clinic
- Professional guidelines from EURETINA, RCOphth, SFP, RANZCO, AAO/ASRS and other societies allow for bilateral injection, provided tht strict asepsis is observed and informed consent exclicitly documents bilateral treatment
- Practical recommendations:
- Treat each eye as a separate procedure using a new vial or pre filled syringe for the second eye
- If compounded drugs are used, prefer different lots in order to minimize the risk of bilateral contamination.
- Patient selection is also important: avoid bilateral injections in patients with active ocular inflammation or systemic frailty
Baruch Kuppermann, MD
Intravitreal injections: devices and robotics
- Many ocular diseases are still seeking improved pharmacological solutions
- Many effective drugs have a relatively short half-life intravitreally, which necessitates frequent injections
- Drug delivery systems provide potential for extended durability
- Gene therapy and cell-based systems allow for intraocular drug production
- Systemic and topical options are being explored
- Extended drug delivery technology to posterior segment is being further refined
- Future generation devices will allow longer duration and increased target specificity
- There is potential for “one and done” or “one and less” therapies, but this may result in a disconnect between treatment and examination intervals


Paolo Lanzetta, MD
Intravitreal injections and AI
- The discussion focused on the evolving role of AI in ophthalmology, highlighting its applications in disease detection, diagnosis, and treatment.
- AI aids in analyzing OCT imaging, predicting disease progression, and personalizing treatment regimens.
- It can forecast visual acuity outcomes and treatment responses, such as anti-VEGF efficacy.
- Through AI-driven retinal image analysis also specific systemic diseases can be identifies, such as cardiovascular diseases and Alzheimer’s disease
- AI holds potential for drug development, and assist in analyzing large datasets from clinical trials
- AI could tailor medical treatment to individual patient profiles, considering genetic makeup, lifestyle and social determinants of health and personalized medicine
